For the quarter ended March 2024, Myriad Genetics (MYGN) reported revenue of $202.2 million, up 11.6% over the same period last year. EPS came in at -$0.01, compared to -$0.21 in the year-ago quarter.The reported revenue represents a surprise of +4.55% over the Zacks Consensus Estimate of $193.4 million. With the consensus EPS estimate being -$0.11, the EPS surprise was +90.91%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall St ...

Myriad Genetics (MYGN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 90.91%. A quarter ago, it was expected that this molecular diagnostic company would post earnings of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of 100%.Over the last four quarters, t ...

Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 megan.manzari@myriad.com matt.scalo@myriad.com "Myriad Genetics entered 2024 with positive momentum as we generated double digit revenue growth over the prior year period, significantly improved year-over-year net loss, and achieved positive adjusted EBITDA in the first quarter," said Paul J. Diaz, President and CEO of Myriad Genetics. "First quarter saw early indications of market share gains i ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Myriad Genetics (MYGN) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock ma ...

SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest GeneSight Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. Of those diagnosed with anxiety and/or depression, half (50%) said they have lost years of their lifetime b ...

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad's prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. Prior studies from other commercial pcfDNA laboratories have reported a broad range of PPV for the 2 ...

Myriad Genetics, Inc. (MYGN) recently announced results from a multi-year, real-world study that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight Psychotropic test. The study consisted of nearly 21,000 patients.Management expects to share additional study results later in 2024.The study’s latest positive initial outcome is a significant stepping stone for Myriad Genetics and is likely to boost the usage of its GeneSight Psychotropic test, part of i ...

Myriad Genetics (MYGN) is well poised for growth in the coming quarters, backed by strong improvement in testing volume across all its businesses. Strong solvency is an added advantage. Yet, foreign exchange headwinds and stiff competition are a concern.In the past six months, this Zacks Rank #3 (Hold) stock has gained 32.8% compared with a 0.6% rise of the industry and a 20% rise of the S&P 500 composite.The renowned genetic testing and precision medicine company has a market capitalization of $1.83 billio ...

SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test. "We are encouraged by the initial results of this study that showed how the proportion of patients with hospitalizations was significantly reduced after GeneSi ...

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad's foundational and proprietary method of preparing cell free DNA. This method ...